|
| Status |
Public on Apr 16, 2015 |
| Title |
Patient 2 (Baseline) |
| Sample type |
RNA |
| |
|
| Source name |
Patient 2 having disease more than 3 months prior to their enrolment and using any combination of cardiac-related medications including ASA, ACEIs, ARBs, β-blockers and statins
|
| Organism |
Homo sapiens |
| Characteristics |
diagnosis: coronary artery disease (CAD)
cell type: PBMCs
|
| Treatment protocol |
PBMCs were isolated from whole blood of the study subjects by density gradient centrifugation method of Boyum , using Histopaque-1077 (Cat no.10771; Sigma, USA).
|
| Growth protocol |
PBMCs were isolated from 2 healthy controls and 4 randomly selected patients for Global Gene expression profiling to screen for the gene signatures for identifying candidate genes as future therapeutic targets.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was isolated from samples with an RNeasy Mini Kit (Catalog No. 74104, QIAGEN, US) using silica column Method, as per manufacturer's protocol.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA samples were prepared according to the standard Affymetrix protocol from 250ng total RNA (GeneChip®HT 3' IVT Express Kit, Affymetrix, USA).
|
| |
|
| Hybridization protocol |
Following fragmentation, 12 ug of cRNA was hybridized for 16 hrs at 45°C on GeneChip®HT 3' IVT.
|
| Scan protocol |
The arrays were washed and stained after 16 hours of hybridization in Fluidic station 450 using appropriate Fluidic Script followed by the scanning of the Array to generate CEL files. Wash and Stain the arrays after 16 hours of hybridization in Fluidic station 450 by using appropriate Fluidic Script followed by the scanning of the Array to generate cell files.
|
| Description |
Gene Expression data from Patient having disease more than 3 months prior to their enrolment and using any combination of cardiac-related medications including ASA, ACEIs, ARBs, β-blockers and statins
PBMCs Isolated from Blood of Patient 2 having disease more than 3 months prior to their enrolment and using any combination of cardiac-related medications including ASA, ACEIs, ARBs, β-blockers and statins
|
| Data processing |
Raw gene expression data was analyzed using the GeneSpringGx 12.0 software (Agilent® Technologies, SantaClara, CA)
Genes that showed more than 2-fold difference between the treated and untreated subjects and with a p-value of <0.05 were considered as differentially expressed. Significant gene ontology categories and pathways that harbor these differentially regulated genes were reported for further biological analysis and interpretation.
|
| |
|
| Submission date |
Apr 17, 2014 |
| Last update date |
Apr 16, 2015 |
| Contact name |
madavan vasudevan |
| E-mail(s) |
madavan.vasudevan@gmail.com
|
| Phone |
+91-9845093355
|
| Organization name |
Theomics International Private Limited
|
| Street address |
Kasturi Nagar
|
| City |
Bangalore |
| State/province |
Karnataka |
| ZIP/Postal code |
560043 |
| Country |
India |
| |
|
| Platform ID |
GPL15207 |
| Series (1) |
| GSE56885 |
Microarray analysis to identify differential molecular signatures in subjects with stable coronary artery disease on standard dosage regimens versus healthy controls |
|
